Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS/MS method

Pharmaceutical Research

Volumn 32, Issue 3, 2015, Pages 1141-1157

  Yan, Tongmeng ^a,b   Gao, Song ^c   Peng, Xiaojuan ^a,b   Shi, Jian ^a,b   Xie, Cong ^a,b   Li, Qiang ^a,b   Lu, Linlin ^a   Wang, Ying ^a   Zhou, Fuyuan ^b   Liu, Zhongqiu ^a,b   Hu, Ming ^c  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

absolute quantification; cytochrome p450; human hepatocellular carcinoma; LC MS MS; UDP glucuronosyltransferases

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; XENOBIOTIC AGENT; ISOENZYME;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DETOXIFICATION; DRUG DISPOSITION; DRUG METABOLISM; ENZYME METABOLISM; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; LIVER CLEARANCE; LIVER MICROSOME; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; COMPLICATION; ENZYMOLOGY; HEPATITIS B; LIQUID CHROMATOGRAPHY; LIVER TUMOR; MASS SPECTROMETRY; REPRODUCIBILITY; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; HEPATITIS B; HUMANS; ISOENZYMES; LIVER NEOPLASMS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 84925508393     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1525-x     Document Type: Article

References (41)

1. Sharma RR. Enzyme Inhibition and Bioapplications. In: Badal S, Shields M, Delgoda R, editors. Cytochrome P450 Enzyme Inhibitors, Nature InTech, 2012, p. 39-56
2. Ruano G, Villagra D, Szarek B, Windemuth A, Kocherla M, Gorowski K, et al. Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients. Biomark Med. 2011;5:439-49.
3. Liu J, Tawa GJ, Wallqvist A. Identifying cytochrome P450 functional networks and their allosteric regulatory elements. PLoS One. 2013;8:e81980.
4. Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45:1121-32.
5. Issue S. The 64th annual meeting of the american association for the study of liver diseases: the liver meeting 2013. HBV Epidemiol Prev Hepatol. 2013;58:607A-26A.
6. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-38.
7. Bisceglie AMD. Hepatitis B, and Hepatocellular Carcinoma. Hepatology. 2009;49:S56-60.
8. Hiyashi N, Popper H, Manns P, Hayashi N. Prevention of Progression in Chronic Liver Disease: An Update on SNMC (Stronger Neo-Minophagen C). In Honour of Hans Popper's 100th Birthday: Springer; 2004.
9. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1983-907.
10. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5:157-67.
11. Congiu M, Mashford ML, Slavin JL, Desmond PV. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos. 2002;30:129-34.
12. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37:2087-94.
13. Iizuka N, Oka M, Hamamoto Y, Mori N, Tamesa T, Tangoku A, et al. Altered levels of cytochrome P450 genes in hepatitis B or C virus-infected liver identified by oligonucleotide microarray. Cancer Genom-Proteomics. 2004;1:53-8.
14. Kawakami H, Ohtsuki S, Kamiie J, Suzuki T, Abe T, Terasaki T. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci. 2011;100:341-52.
15. Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC. Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res. 2013;12:4402-13.
16. Fallon JK, Harbourt DE, Maleki SH, Kessler FK, Ritter JK, Smith PC. Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS. Drug Metab Lett. 2008;2:210-22.
17. Harbourt DE, Fallon JK, Ito S, Baba T, Ritter JK, Glish GL, et al. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem. 2012;84:98-105.
18. Sato Y, Nagata M, Kawamura A, Miyashita A, Usui T. Protein quantification of UDP-glucuronosyltransferases 1A1 and 2B7 in human liver microsomes by LC-MS/MS and correlation with glucuronidation activities. Xenobiotica. 2012;42:823-9.
19. Zhu L, Yang X, Zhou J, Tang L, Xia B, Hu M, et al. The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Food Chem Toxicol. 2013;51:396-403.
20. Xu B, Gao S, Wu B, Yin T, Hu M. Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities. J Pharm Biomed Anal. 2014;88:180-90.
21. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos. 2009;37:1759-68.
22. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006;57:685-92.
23. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69:223-40.
24. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-94.
25. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997;25:1-4.
26. Kaivosaari S, Finel M, Koskinen M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica. 2011;41:652-69.
27. Eric L, Hugo G, Kim J, Jonanie L, Chantal G. Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a New splicing event at the UGT1A locus. Hepatology. 2007;45:128-37.
28. UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. M. Cristina de A, Elisabet S, Remi T, Cinta P, Veronique N, Carlos JC. Biochemical Pharmacology. 2011;81:60-70
29. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40:83-92.
30. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123:369-75.
31. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331-9.
32. Roepstorff P, Fohlman J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed Mass Spectrom. 1984;11:601.
33. Johnson RS, Martin SA, Biemann K, Stults JT, Watson JT. Novel fragmentation process of peptides by collision-induced decomposition in a tandem mass spectrometer: differentiation of leucine and isoleucine. Anal Chem. 1987;59:2621-5.
34. Hu DG, Rogers A, Mackenzie PI. Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. Mol Pharmacol. 2014;85:887-97.
35. Theoret MR, Cohen CJ, Nahvi AV, Ngo LT, Suri KB, Powell Jr DJ, et al. Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther. 2008;19:1219-32.
36. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New boost York, NY: Springer; 2010.
37. Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer. 2004;90(12):2349-55.
38. Piraud M, Vianey'Saban C, Petritis K, Elfakir C, Steghens J, Bouchu D. Ion'pairing reversed'phase liquid chromatography/electrospray ionization mass spectrometric analysis of 76 underivatized amino acids of biological interest: a new tool for the diagnosis of inherited disorders of amino acid metabolism. Rapid Commun Mass Spectrom. 2005;19(12):1587-602.
39. Nagy K, Takáts Z, Pollreisz F, Szabó T, Vékey K. Direct tandem mass spectrometric analysis of amino acids in dried blood spots without chemical derivatization for neonatal screening. Rapid Commun Mass Spectrom. 2003;17(9):983-90.
40. Council of Europe. European Pharmacopoeia 5.0. Strasbour. 2005; 86-92.
41. Viswanathan CT, Bansal S, Booth B, Destefano A, Rose M, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24(10):1962-73.